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Purpose: Steroids may play a role in preventing the early recurrence of atrial fibril-
lation (AF) after radiofrequency catheter ablation (RFCA). However, optimal doses 
and route of steroid delivery have not yet been determined. This study evaluated the 
effect of two different doses of a single bolus injection of steroids on AF recurrence 
after RFCA. Materials and Methods: Of 448 consecutive AF patients who under-
went RFCA, a single steroid bolus was injected into 291 patients. A low-dose ste-
roid group (n=113) received 100 mg of hydrocortisone and a moderate-dose steroid 
group (n=174) received 125 mg of methylprednisolone. We used propensity-score 
matching to select patients as follows: control (n=95), low-dose (n=95), and moder-
ate-dose steroid groups (n=97). Results: Pericarditis developed in 1 (1.1%) control 
patient, 2 (2.1%) low-dose patients and 0 moderate-dose patients. Maximum body 
temperature and C-reactive protein were significantly decreased in the moderate-
dose steroid group compared to the other groups (p<0.01). The number of patients 
of early AF recurrence (≤3 months) did not differ among three groups. Early recur-
rence was 24 (25%) in the control, 24 (25%) in the low-dose and 25 (26%) in the 
medium-dose groups (p=0.99). Compared with control group, low-dose or moder-
ate-dose steroid treatment did not effectively decrease mid-term (3‒12 months) AF 
recurrence [22 (23%) vs. 23 (24%) vs. 18 (19%); p=0.12]. Conclusion: A single in-
jection of moderate-dose steroid decreased inflammation. However, single bolus in-
jections of low-dose or moderate-dose steroids were not effective in preventing im-
mediate, early or midterm AF recurrence after RFCA.
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INTRODUCTION
The incidence of atrial fibrillation (AF) is increasing. AF is associated with a consid-
erable number of comorbidities including a 3-fold increase in the risk of heart failure 
and a 5-fold increase in the risk of stroke.1-3 Radiofrequency catheter ablation 
(RFCA) is an effective treatment for drug-refractory AF with 33‒86% of patients 
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ty Hospital (Seoul, Korea) from July 2007 through Decem-
ber 2012. All patients were newly enrolled in this study and 
none had a history of ablation. As a control group, 161 AF 
patients who underwent radiofrequency ablation for AF 
during the same period were analyzed. Patients who had 
previously undergone RFCA were excluded. All patients 
had symptomatic, paroxysmal or persistent AF. The deci-
sion to treat patients with low-dose or moderate-dose ste-
roids was made by operating physicians. One physician 
(Dr. Joung) used a strategy of treatment with corticosteroids 
after catheter ablation and the other physicians (Dr. Lee and 
Dr. Pak) did not use this strategy. Patients were randomly 
assigned to operating physicians without this information. 
All operating physicians used the same ablation protocol. 
In this triple cohort study, the corticosteroid group had 
two subgroups based on corticosteroid potency. The low-
dose steroid group (n=113) received 100 mg hydrocortisone 
sodium succinate (Solu-Cotef, Pfizer Manufacturing, Puurs, 
Belgium) in 5 mL of 0.9% sodium chloride. The moderate-
dose steroid group (n=174) received a bolus injection of 
methyl prednisolone 125 mg (Solu-Medrol, Pfizer Manu-
facturing, Puurs, Belgium) in 5 mL of 0.9% sodium chlo-
ride (625 mg as in hydrocortisone equivalence). Steroid solu-
tions were administered intravenously within 30 minutes 
after RFCA. Patients in the control group (n=161) were treat-
ed conservatively without steroids after ablation. From the 
cohort, we selected age- and gender-matched cohorts by 
propensity scores. The final cohorts were control (n=95, 80 
men), low-dose (n=95, 80 men), and moderate-dose steroid 
group (n=97, 82 men) (Fig. 1).
Paroxysmal AF was defined as an AF episode that spon-
taneously terminated and lasted for more than 30 s, but less 
than 7 days. Persistent AF was defined as an AF episode 
that either lasted longer than 7 days or required termination 
by cardioversion, either with anti-arrhythmic drugs (AADs) 
or by direct current cardioversion. All AADs were discon-
tinued at 5 half-lives before the ablation procedure. Other 
drugs were administered throughout the study period. The 
study protocol was approved by the Institutional Review 
Board of Severance Cardiovascular Hospital, Seoul, Korea 
and complied with the Declaration of Helsinki.
Catheter ablation 
Three-dimensional geometry of the left atrial (LA) was re-
constructed with a CARTO (Biosense Webster, Inc., Dia-
mond Bar, CA, USA) or NavXTM (St. Jude Medical, Inc., St. 
Paul, MN, USA) electroanatomic mapping system. Before 
achieving favorable outcomes.4-6 However, studies on long-
term outcomes after RFCA commonly report recurrence of 
AF, especially within the first few weeks after RFCA.7 For 
early recurrences, inflammation during RFCA is suggested to 
be a major precipitating factor. The role of inflammation in 
initiating and perpetuating AF is under investigation since in-
flammation is suggested to be an important cause of the high 
incidence of post-operative AF in cardiac surgeries.8,9 A few 
studies reported independent relationships between inflam-
matory markers and AF incidence. These studies propose 
that acute inflammation transiently induces electrical and 
structural remodeling of the left atrium.10 According to stud-
ies that investigated early AF recurrence after RFCA, inflam-
mation might cause early recurrence, as reflected in elevated 
inflammatory markers and body temperatures.11,12
To prevent early AF recurrence after RFCA, corticosteroid 
injection is used to reduce post-procedure inflammation. Cor-
ticosteroids are potent inhibitors of the pro inflammatory cas-
cade. Corticosteroids reduce inflammatory markers such as 
interleukin (IL)-6, IL-8, tumor necrosis factor α, C-reactive 
protein (CRP), and oxygen-free radicals after cardiac sur-
gery.13-16 A randomized controlled trial by Koyama, et al.12 
showed that a small amount of corticosteroid administered 
after RFCA seems to prevent immediate AF recurrence. 
However, the use of corticosteroids for secondary preven-
tion of AF has not yet been confirmed and has not been thor-
oughly studied in a large population. In addition, an appro-
priate corticosteroid dosage has not been determined. Side 
effects of corticosteroids such as infections, hyperglycemia, 
gastrointestinal bleeding, adrenal suppression, hallucination, 
and depression have been acknowledged, and physicians re-
alize that the benefits of steroids must outweigh their poten-
tially dangerous side effects. Moreover, high-dose steroids 
are reported to cause ventricular arrhythmia and even pro-
mote AF.13 Thus, studies investigating adequate minimal 
dose for steroids and appropriate method of steroid adminis-
tration that will prevent early AF recurrence after RFCA are 
warranted. This study evaluated the effect of a single bolus 
intravenous injection of low-dose or moderate-dose cortico-
steroids on preventing AF recurrence after RFCA. 
MATERIALS AND METHODS
Patients
This study enrolled 448 patients with drug-resistant AF who 
underwent RFCA. Patients were treated at Yonsei Universi-
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catheter ablation. 
After discharge, all patients underwent follow-up at 1 
week and 1 month post-procedure and every three months 
thereafter. At each hospital visit, patients underwent 12-lead 
electrocardiography and intensive questioning regarding ar-
rhythmia-related symptoms (palpitation, chest discomfort 
and dizziness) since the previous follow-up visit. Holter 
monitoring for 24 hour was performed at 1 and 3, 6, 12, 18, 
and 24 months after RFCA. Portable event electrocardio-
graphic monitoring (EV-101, Parama-Tech, Fukuoka, Ja-
pan) was performed to evaluate arrhythmic assessment in 
patients with intermittent symptoms. 
We defined early recurrence as any episode of AF or atri-
al tachycardia (AT) of at least 30 seconds that occurred 
within 3 months after AF ablation. Mid-term recurrence was 
defined as any AF or AT of at least 30 seconds that oc-
curred between 3 and 12 months.18
Three patients: 1 (1.1%) from the control group, and 2 
(2.1%) from the low-dose group developed pericarditis af-
ter RFCA; these patients were excluded from the analysis 
of recurrence because they were treated with higher doses 
of corticosteroids for pericarditis.
If electrocardiograms (ECGs) showed any AF episodes 
during the follow-up, patients received a diagnosis of clini-
cal recurrence of AF, irrespective of the presence of symp-
toms.19 Patients with AF recurrence were treated temporarily 
with Class I, II, III, and/or IV AADs, and AADs were dis-
ablation, triggers were evaluated after direct current cardio-
version of AF. Circumferential pulmonary vein isolation 
(PVI) was performed on all patients using a 3.5-mm irrigat-
ed-tip catheter (ThermoCool, Biosense Webster, Diamond 
Bar, CA, USA) with the maximum temperature set at 50ºC 
and power output 25‒35 W. We used a circular mapping 
catheter (Lasso, Biosense Webster) to confirm PVI. The end-
point of the PVI was creation of a bidirectional conduction 
block between the atrium and the pulmonary veins (PVs). A 
cavo-tricuspid isthmus block line was created with confirma-
tion of the bidirectional block. After PVI, if AF was sus-
tained, additional ablation, consisting of linear ablation, com-
plex fractionated atrial electrogram (CFAE) ablation and/or 
superior vena cava (SVC) isolation, was performed.17 If AF 
did not terminate, sinus rhythm was restored by transthoracic 
cardioversion.17
Follow-up 
Patients remained hospitalized under continuous rhythm 
monitoring (IntelliVue Telemetry System, Philips Health-
care, Amsterdam, the Netherlands) for at least 48 hours after 
RFCA with subsequent follow-up. Body temperature was 
measured on the morning of the ablation and every 8 hours 
for 72 hours after ablation using an eardrum thermometer 
(Infrared thermometer IRT4020, Braun GmbH, Kronberg, 
Germany) in the ear canal. CRP, C3, C4 levels and complete 
blood cell counts were measured 1 day and 1 week after 
Fig. 1. Flow diagram describing outcome of RFCAs. AF, atrial fibrillation; RFCA, radiofrequency catheter ablation.
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morbidities, and echocardiographic parameters were not dif-
ferent among the 3 groups. Although the proportion of pa-
tients taking class III AADs was different among the 3 groups 
[39 (41%) vs. 22 (23%) vs. 30 (31%), p=0.04], other medica-
tions were not significantly different among the groups. 
Ablation procedure 
Catheter ablation parameters and recurrence rates of AF are 
presented in Table 2. Circumferential PVI was successfully 
performed in all patients, and bidirectional conduction block 
was created at all 4 PVs. A cavo-tricuspid isthmus block line 
with confirmation of bidirectional block was successfully 
created in 81 (90%) in the control group, 88 (98%) in the 
low-dose group, and 84 (91%) in the moderate-dose group. 
No differences were observed in linear ablation, CFAE or su-
perior vena cava (SVC) isolation, except posterior box and 
lateral box linear ablations. Total procedure duration time, to-
tal fluoroscopy time and duration of RFCA were not statisti-
cally different among the three groups. 
Inflammatory responses and pericarditis 3 days after 
ablation 
We measured white blood cell (WBC) counts, CRP, and body 
temperature after RFCA (Table 3). Patients in the moderate-
continued if stable sinus rhythm was maintained. Discontin-
uation of AADs was attempted in patients whose recurrent 
AF disappeared after temporary treatment; if sinus rhythm 
was maintained, the drugs were stopped permanently. 
Statistical analysis 
SPSS version 19.0 (SPSS Inc., Chicago, IL, USA) was 
used for statistical analysis. Continuous variables were ex-
pressed as mean±standard deviation, and categorical vari-
ables were described using numbers or percentages. Com-
parisons of differences between two groups were made by 
chi-square analysis and unpaired Student’s t-test. Time to 
atrial fibrillation recurrence 31 days after catheter ablation 
was estimated by the Kaplan-Meier method, with compari-
sons made using the log-rank test. A p value <0.05 was 
considered statistically significant.
RESULTS
 
Baseline characteristics 
Baseline clinical characteristics are shown in Table 1. The 
groups contained 95, 95, and 97 patients, respectively. Base-
line characteristics of mean age, gender predominance, co 
Table 1. Baseline Characteristics 
Control 
(n=95)
Low-dose steroid 
(n=95)
Moderate-dose steroid 
(n=97)
p value
Age, yrs 56±10 56±9 56±10 0.93
Male sex, n (%) 80 (85) 80 (84) 82 (84) 0.98
Paroxysmal AF, n (%) 60 (63) 58 (63) 61 (64) 0.96
Comorbidities, n (%)
    Congestive heart failure 2 (2) 3 (3) 5 (5) 0.44
    Hypertension 40 (42) 46 (48) 49 (52) 0.38
    Age >75 yrs 2 (2) 2 (2) 2 (2) 0.73
    Diabetes 10 (10) 6 (6) 13 (14) 0.24
    Stroke 3 (3)    6 (6.3)    9 (9.6) 0.19
    Coronary artery disease 2 (2)    1 (1.1)    3 (3.2) 0.54
Echocardiographic parameters
    LA diameter, mm 42±6 41±5    42±7 0.74
    LV end-diastolic dimension, mm 52±8 49±5 50.6±4 0.15
    LV ejection fraction, % 61±6 64±7    62±9 0.79
Antiarrhythmic drugs, n (%)
    Class I c 54 (57) 61 (64) 61 (63) 0.54
    Class III 39 (41) 23 (24) 30 (31) 0.04
Medications, n (%)
    ACEIs or ARBs 17 (18) 22 (23) 24 (26) 0.41
    Beta-blockers   5 (18) 15 (20) 24 (26) 0.51
    Statins 11 (12) 15 (16) 21 (23) 0.09
ACEI, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; LA, left atrial; LV, left ventricular.
Values are mean±SD. 
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3 groups. Early recurrence was 24 (25%) in the control, 24 
(25%) in the low-dose and 25 (26%) in the medium-dose 
groups (p=0.99).  Low-dose and moderate-dose steroids did 
not decrease mid-term AF recurrence (3‒12 months) [22 
(23%) vs. 23 (24%) vs. 18 (19%); p=0.12] after ablation, 
compared with controls (Table 3).
Fig. 2 shows Kaplan-Meier survival curves for AF recur-
rence in each group, with no significant differences in the 
rates of patients with no AF recurrence (p=0.11 by log-rank 
test). The first three months was presumed to be a blanking 
period, because AF recurrences early after RFCA are consid-
ered to be transient.17 By multivariate Cox-regression analy-
sis, persistent AF (HR 1.67, 95% CI 1.18‒2.37; p=0.04) was 
the only independent predictor of late recurrence after ad-
justing for steroid use, age >75, diabetes mellitus, LA size 
and ablation time. 
DISCUSSION
The main finding of this study was that a single bolus injec-
tion of low-dose or moderate-dose corticosteroids did not 
prevent AF recurrence after RFCA. Moderate doses of corti-
dose steroid group had the lowest maximal body temperature 
(37.1±0.5°C control vs. 37.0±0.5°C low-dose vs. 36.8±0.2°C 
moderate-dose; p<0.01) and the lowest CRP (23.7±13.4 mg/
L control vs. 20.3±12.8 mg/L low-dose vs. 5.2±8.4 mg/L 
moderate-dose; p<0.01). Although not statistically significant, 
the control group had the highest mean WBC count com-
pared to low- and moderate-dose steroid group (9279±2668/
μL control vs. 8880±2332/μL low-dose vs. 9122±2559/μL 
moderate-dose; p=0.61). Post-RFCA complications, specifi-
cally development of pericarditis, were 1 (1.1%) in control, 2 
(2.1%) in low-dose and 0 in moderate-dose.
Post-ablation course and AF recurrence
No major complications were documented in any group 
during the follow-up period, which had a median of 26±12 
months. Rates of infection and hematoma were not differ-
ent among the 3 groups. One year after RFCA, 16 of 24 
(67%) early AF recurrence patients in control group main-
tained sinus rhythm (Fig. 1). For low-dose and moderate-
dose steroid group, 19 of 24 (79%) and 19 of 25 (76%) early 
AF recurrence maintained to be sinus rhythm. We compared 
recurrence rates among the 3 groups. The number of patients 
of early AF recurrence (≤3 months) did not differ among the 
Table 2. Catheter Ablation
Control 
(n=95)
Low-dose steroid 
(n=95)
Moderate-dose steroid 
(n=97)
p value
Ablation procedure, n (%)
    Circumferential PV isolation 95 (100) 95 (100)   97 (100) 0.37
    CTI ablation 81 (90) 88 (98) 84 (91) 0.09
    Linear ablation 35 (37) 36 (38) 35 (36) 0.95
    CFAE 7 (8) 2 (2) 7 (7) 0.19
    SVC isolation 6 (7) 2 (2) 14 (15) 0.01
Catheter ablation (min)
    Total duration of procedure 192±52 182±46 168±40 0.13
    Total fluoroscopy time   48±16   58±19   43±13 0.68
    Duration of RF ablation   86±24   77±27   68±23 0.98
CFAE, complex fractionated atrial electrogram; CTI, cavo-tricuspid isthmus ablation; PV, pulmonary vein; RF, radiofrequency; SVC, superior vena cava.
Values are mean±SD. 
Table 3. Inflammation Markers, Body Temperature, Pericarditis and Recurrence
Control 
(n=95)
Low-dose steroid 
(n=95)
Moderate-dose steroid 
(n=97)
p value
WBC (/μL)   9279±2668   8880±2332   9122±2559 0.61
CRP (mg/L)   23.7±13.4   20.3±12.8   5.2±8.4 <0.01
Maximal body temperature (°C) 37.1±0.5 37.0±0.5 36.8±0.2 <0.01
Pericarditis, n (%)    1 (1.1)    2 (2.1) 0 (0) 0.52
Recurrence, n (%)
    Early (≤3 months) 24 (25) 24 (25) 25 (26) 0.99
    Mid-term (3–12 months) 22 (23) 23 (24) 18 (19) 0.12
CRP, C-reactive protein; WBC, white blood cell. 
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rence are not fully established, even in cardiac surgery stud-
ies. An intermediate-dose group (50‒210 mg dexametha-
sone, 1333‒5600 mg as in hydrocortisone equivalence) 
significantly reduced incidences of AF after cardiothoracic 
surgery, compared with placebo.21,24 Both low-dose (<200 
mg/d) and high-dose steroids (>1000 mg/d) were ineffective 
compared to moderate doses (200‒1000 mg/d) of cortico-
steroid for preventing AF after cardiac surgery.20 However, 
high-dose steroids do not prevent postoperative AF.21,25,26 
Moreover, high-dose steroids induced AF by modulating 
potassium channels. Our previous study showed that a bo-
lus injection of low-dose steroids was not effective in pre-
venting AF recurrence.27
Whether a single bolus injection of steroids is effective 
for prevent inflammation is unknown. A previous study that 
investigated steroid doses to affect survival in acute respira-
tory distress syndrome suggested that more than a single 
bolus injection of steroids was effective at reducing system-
ic inflammatory responses.28 In this study, however, a single 
bolus injection of moderate-dose steroids significantly low-
ered inflammation after RFCA without noticeable side ef-
fects of corticosteroid. 
Study limitations
This study had several limitations. First, data were reviewed 
retrospectively and low-dose or moderate-doses of steroids 
were not randomly allocated. However, using propensity 
score matching, no significant difference was seen in patient 
baseline characteristics, ablation protocol, or procedural 
costeroids resulted in decreased inflammation after RFCA, 
which was reflected in significantly lower WBC counts, 
CRP, and body temperature, compared to the control group. 
However, the decrease in inflammatory markers was not 
accompanied by a decreased incidence in recurrence. Our 
data suggested that a single bolus injection of low-dose or 
moderate-dose corticosteroids might not be sufficient to 
prevent post-ablation AF recurrence. 
Steroids and AF prevention 
The use of corticosteroids to prevent AF has mainly been 
evaluated in cardiothoracic surgery.20,21 Meta-analyses re-
vealed that corticosteroid therapy is associated with a de-
crease in more than 50% postoperative AF episodes,20 al-
though heterogeneity in variable dosages and steroid dosing 
intervals must be considered. AF after cardiac and non car-
diac surgery had been known to be usually prevented with 
steroid, however, it must be noted that the surgery is differ-
ent from catheter ablation, causing more severe systemic 
inflammation and infection. 
Dernellis and Panaretou22 demonstrated that 16 mg meth-
yl prednisolone for 4 weeks, tapering to 4 mg for 4 months, 
significantly reduced AF recurrence (50% vs. 2.9%, p< 
0.001). Koyama, et al.12 reported that intravenous hydrocor-
tisone (2 mg/kg) immediately after ablation and oral pred-
nisolone (0.5 mg/kg/day) for 3 days after the procedure re-
sulted in a marked decrease in immediate AF recurrence. 
Moreover, AF-free states were maintained without AADs in 
a corticosteroid-treated group (85% vs. 71%, p<0.05). The 
efficacy of steroids and proper doses and dosing intervals to 
prevent AF recurrence after RFCA are still debatable. 
In this study, single doses of steroids did not prevent AF 
recurrence after RFCA. The total dosage of steroid was not 
different between our study and the study by Koyama, et al.12 
For example, a total dosage of steroid given to a 60 kg body 
weight patient was 625 mg as in hydrocortisone equiva-
lence for moderate-dose group of our study, while 480 mg 
as in hydrocortisone equivalence was injected in the study 
by Koyama, et al.12 Therefore, the negative result of this 
study is more likely caused by administration method. Re-
cently, Nascimento, et al.23 reported that a single prophylac-
tic corticosteroid before AF ablation did not prevent system-
ic inflammation or alter the healing of the ablation lesion in 
pigs. This result is consistent with our study. 
Dosage and route of steroids
Effective doses or dosing intervals to decrease AF recur-
Fig. 2. Kaplan-Meier survival curves for AF recurrence. No difference was 
seen in cumulative rates of absence of late AF recurrence among control, 
low-dose, and moderate-dose patients (p=0.11 by log-rank test). AF, atrial 
fibrillation.
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man CI. Effect of perioperative corticosteroid use on the incidence 
of postcardiothoracic surgery atrial fibrillation and length of stay. 
time among the 3 groups. Second, since we used conven-
tional electrocardiogram and ambulatory Holter monitoring, 
asymptomatic AF recurrence might not be detected. A con-
tinuous recording for a longer period would provide more 
insight into the efficacy of steroids.
       
Conclusions
A single injection of moderate-dose steroid decreased in-
flammation. However, single bolus injections of low-dose 
or moderate-dose steroids were not effective in preventing 
immediate, early or midterm AF recurrence after RFCA. 
Our study suggested that a single dose of corticosteroids 
might not be effective to prevent AF after RFCA.
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